This dual-agonist approach distinguishes tirzepatide from single GLP-1 receptor agonists like semaglutide
Our previously published retrospective cohort study suggests that GLP-1 (glucagon-like peptide-1) analogs may be superior to alternative regimens for both glycemic and weight control in patients on antipsychotic plus/minus antidepressant medications
Human data is limited to small, older studies with mixed/modest results
Meet our experts Kristi Kratovil , MD, clinical lead for obesity medicine at Sentara Health Weight Loss Solutions in Norfolk, Va., and diplomate of the American Board of Obesity Medicine Richele Corrado , DO, spokesperson for The Obesity Society in Washington, D.C., and medical director at Revolution Medicine, Health and Fitness Our health content is for informational purposes only and is not intended as professional medical advice
This is a purchasing and menu view, not a dosing chart